Proactive Investors - Run By Investors For Investors

QBioMed appoints Yale psychologist to advisory committee

Dr Pamela Ventola works at Yale University’s Child Study Center where she focuses on behavioral treatments for autism
empty board room
Q BioMed’s drug QBM-001 is being developed for the treatment of autistic children

Q BioMed Inc (OTCQB:QBIO), the New York biotech, announced Wednesday that Dr. Pamela Ventola of Yale University has joined its advisory committee for its QBM-001 clinical program, which is advancing its drug treatment for autistic toddlers.

Dr Ventola now works as a clinical psychologist and assistant professor at Yale University’s Child Study Center where she focuses on behavioral treatments for autism spectrum disorders.

READ: Q BioMed partners with SRI International for autism drug QBM-001

A licensed clinical psychologist, Dr. Ventola is an expert in pediatric neuropsychology and developmental disabilities. She also holds the position of senior science director at the Rare Disease and Pediatric Center of Excellence at Cogstate, a company that supports pharmaceutical companies in clinical trial design.

“Children with [autism spectrum disorders] need safe, effective and targeted treatments that are tested under conditions that take their best interests into consideration to ensure a successful trial,” said Dr. Ventola in a statement. “I am inspired that Q BioMed has the same vision and am excited to ensure QBM-001 has the best chance to help their targeted subgroup.”

Denis Corin, CEO of QBioMed, says Ventola’s expertise will prove helpful as QBioMed prepares its investigational new drug application for QBM-001 to submit to the US Food and Drug Administration.

“[Ventola] is a leader in clinical trial design and biomarker research for the autism spectrum, which is a perfect fit for the subgroup Q BioMed is targeting,” Corin said. “Dr. Ventola will be an asset to our development program as we prepare our Investigational New Drug Application (IND) for submission to the FDA in this important indication for which no drugs are currently available.”

Q BioMed’s drug treatment QBM-001 is being developed and tested for the treatment of minimally verbal and non-verbal toddlers with an autism spectrum disorder.

Contact Ellen Kelleher at [email protected]

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use